BlueChew Appears in 24.2% of AI Answers. Here's Our Five-Step Plan to Improve Its AI Visibility.
This report supports CiteWorks Studio's examination of how AI search is recommending ED Treatment Pills. For more detail, you can also read ED Treatment Pills: AI Visibility Discovery Index.
On this report
Browse sections
- Answer Capsule
- Current AI visibility
- What changed since last month
- Next Step
- Step 1. Measure
- Step 2. Make the website consistent
- Step 3. Align the external narrative
- Step 4. Optimize priority company pages
- Step 5. Publish around buyer questions
- Our 90-day action plan
- Methodology
- Our first three priorities
- Learn More
Key Takeaways
- BlueChew is mentioned in 68 of 281 benchmark answers, but it is recommended far less often than it is mentioned.
- The main issue is not presence alone; the brand rarely reaches top-three or first-place positions in answers.
- The report identifies conflicting claims around pricing, free trials, and product ingredients that need primary-source verification.
- The action plan focuses on page consistency, third-party citation review, owned comparison pages, and content built around buyer questions.
Answer Capsule
In November 2026, BlueChew appeared in 68 of 281 AI answers included in the ED Treatment Pills benchmark (24.20%). It received 33 recommendations (11.74%), with 16 Top 3 placements and 2 first-place recommendations. A mention means the company appeared in an answer; a recommendation means the answer affirmatively endorsed it.
Our plan compares the company with its competitors, checks conflicting AI claims against reliable sources, and identifies website pages, third-party sources and buyer questions to address. The historical results show how the figures changed across available months. Different monthly samples limit those comparisons, and conflicting AI claims require verification before corrections are proposed.
Current AI visibility
Questions This Section Answers
- How do BlueChew mentions, recommendations and placements compare with its ED Treatment Pills peers?
BlueChew recorded 68 mentions (24.20%) and 33 recommendations (11.74%) across 281 answers included in the benchmark. Top 3 placements numbered 16; first-place recommendations numbered 2. Framing among its mentions was 34 positive, 31 neutral and 3 negative.
Rank | Company | Mentions | Mention rate | Recommendations | Recommendation rate | Top 3 | Top 3 rate | #1 | #1 rate |
|---|---|---|---|---|---|---|---|---|---|
1 | Hims | 252 | 89.68% | 189 | 67.26% | 144 | 51.25% | 75 | 26.69% |
2 | Ro | 237 | 84.34% | 179 | 63.70% | 131 | 46.62% | 20 | 7.12% |
3 | GoodRx Care | 214 | 76.16% | 168 | 59.79% | 122 | 43.42% | 62 | 22.06% |
4 | plushcare | 111 | 39.50% | 92 | 32.74% | 40 | 14.23% | 6 | 2.14% |
5 | Lemonaid Health | 98 | 34.88% | 79 | 28.11% | 28 | 9.96% | 1 | 0.36% |
6 | BlueChew | 68 | 24.20% | 33 | 11.74% | 16 | 5.69% | 2 | 0.71% |
6 | Rex MD | 51 | 18.15% | 33 | 11.74% | 17 | 6.05% | 1 | 0.36% |
8 | 20 | 7.12% | 20 | 7.12% | 12 | 4.27% | 5 | 1.78% | |
9 | Optum | 22 | 7.83% | 17 | 6.05% | 14 | 4.98% | 7 | 2.49% |
10 | K Health | 17 | 6.05% | 15 | 5.34% | 5 | 1.78% | 1 | 0.36% |
BlueChew appears in roughly a quarter of the answers reviewed, but it is recommended far less often than it is mentioned. That gap is the central visibility issue: the brand is present in the conversation without being the answer the assistant puts forward. Reach and endorsement are separate measures here, and the report keeps them apart.
Position is a further distinction. BlueChew's shortlist placements are limited and its first-place appearances are rare, so even when it is endorsed it seldom leads. The agency would treat presence, endorsement and position as three separate scorecard lines, because improving one does not automatically lift the others.
Framing is mostly positive or neutral, with few negative mentions. That is a reasonable base, but positive wording alone does not amount to a recommendation. The practical question is what would move an assistant from describing BlueChew to endorsing it, and that is what the proposed work sets out to test.
What changed since last month
Questions This Section Answers
- How did BlueChew counts and coverage differ across the available monthly snapshots?
Metric | Oct 2026 | Nov 2026 |
|---|---|---|
Mentions | 64 / 296 (21.62%) | 68 / 281 (24.20%) |
Recommendations | 38 / 296 (12.84%) | 33 / 281 (11.74%) |
Top 3 recommendations | 27 / 296 (9.12%) | 16 / 281 (5.69%) |
#1 recommendations | 4 / 296 (1.35%) | 2 / 281 (0.71%) |
Only months with verified results are shown. Monthly sample coverage is listed in Methodology.
From October 2026 to November 2026, BlueChew's mention count rose from 64 to 68, while its recommendation count fell from 38 to 33. The recommendation rate was 12.84% and 11.74% respectively.
Between the two selected months, BlueChew's mention count moved up slightly while its recommendation count moved down. The recommendation rate also eased. These are observed movements in separate samples, and the report does not establish why they occurred.
The shortlist and first-place counts both fell, which matters more than the mention movement because those are the positions closest to an endorsement. A brand can be named more often and still be endorsed less often; the two lines should be read independently rather than as a single trend.
The samples differ between months, so the comparison describes what was recorded rather than a like-for-like change. The agency would carry both months into the scorecard as separate observations and avoid drawing a direction from two points.
AI recommendation trend
Observed recommendation rate (%), Oct 2026 to Nov 2026
- BlueChew-1.10 ppOct 202612.84%Nov 202611.74%
Separate selected monthly samples. Missing points are unavailable, not zero. Provider/prompt equivalence is unverified; rate movement does not demonstrate causation.
/ Take the next step
Want to Understand Your AI Citation Footprint?
We start every engagement with a full audit of how AI systems reference your brand today.
Measurable, Repeatable Programme
Build a durable foundation of credible citations that compounds over time and continues to influence AI answers as new queries emerge
Citation Architecture Review
Identify which high-authority community sources are and aren't working in your favour across AI platforms.
AI Visibility Audit
Understand exactly how LLMs are referencing your brand today and which sources are shaping those answers.
Step 1. Measure
Questions This Section Answers
- What should the agency measure and verify first for BlueChew?
AI answers contained 16 conflicting claims about BlueChew: 3 critical, 1 high, 12 medium, 0 low. Of these, 4 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.
The benchmark surfaced a set of conflicting claims about BlueChew, a small number of which were rated critical or high priority. Those ratings are a triage tool for fact-checking, not a finding that anyone made an error. They tell the client where to look first, not what the answer should be.
The proposed first step pairs a visibility comparison with a claim list. The comparison shows where BlueChew sits against the other services in the answers; the claim list shows which statements about the brand most need checking against primary sources. Together they let the client set priorities on evidence rather than impression.
Each claim would be assigned an owner and an evidence requirement before any correction is considered. Some apparent conflicts may resolve once the entity, date and source are confirmed, so the register records status rather than assuming a fix is needed.
Step 2. Make the website consistent
Questions This Section Answers
- Which recorded claim differences about BlueChew should be verified before proposed page edits?
Review topic | Severity | Recorded AI claim A | Recorded AI claim B |
|---|---|---|---|
monthly price range | medium | starts ~$25/mo; $25–$135/mo | starts ~$30/mo; typical $30–$100+/mo |
free trial availability | high | no free trial; only free consultation / discounted first pack | free trial month for new subscribers |
monthly starting price | medium | ~$20/month | ~$25/month |
BlueChew Gold ingredients (apomorphine/oxytocin inclusion) | medium | Gold combines sildenafil, tadalafil, apomorphine, and oxytocin | Gold uses sildenafil, tadalafil, and apomorphine (no oxytocin) |
Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.
The disputed topics cluster around price, free-trial availability and what the Gold product contains. The report records two competing AI statements for each and deliberately does not decide which is true. Resolving them requires current primary-source verification, including checking dates, since an older statement may simply reflect an earlier offer.
The proposed work is a set of conditional page briefs: for each topic, a brief that states what the page should clarify once the facts are confirmed. The free-trial question is rated highest, so it would be verified first. Price ranges and product composition follow.
Where verification shows the current page is already accurate, the brief becomes a no-change decision rather than an edit. That keeps the work honest and avoids rewriting pages to match an unverified AI statement.
Step 3. Align the external narrative
Questions This Section Answers
- Which cited third-party pages are relevant to fact review for BlueChew?
Cited page selected for review | Citation appearances in all captured answers | Answers mentioning the company | Conflicting claims linked to this page |
|---|---|---|---|
https://medicalnewstoday.com/articles/bluechew-vs-hims | 38 | 0 | 10 |
https://hims.com/erectile-dysfunction | 38 | 17 | 9 |
https://innerbody.com/bluechew-vs-hims | 44 | 2 | 8 |
https://meetaugust.ai/en/articles/hims-vs-bluechew | 16 | 1 | 8 |
https://hims.com/blog/hims-vs-bluechew | 38 | 0 | 8 |
https://ubiehealth.com/doctors-note/bluechew-vs-hims-vs-roman-ed-service-comparison-4233e1 | 25 | 3 | 6 |
These pages were selected because they relate to the company in the captured answers. Their current contents still need checking before any correction request. A page linked to a conflicting claim is not necessarily its cause, and the same answer may contribute to more than one row.
Several third-party comparison pages are cited repeatedly in the captured answers, and some carry conflicting claims about BlueChew. A citation is not evidence that a page caused a claim, and the same answer can touch more than one page. The current contents of these pages still need checking before any request is made.
The proposed work is a source review: read each selected page, confirm what it currently says, and note where it conflicts with verified facts. Only then would the agency consider an evidence-backed request to a publisher, framed as a correction with supporting sources rather than an assumption of error.
Publisher control is limited, so requests are recorded separately from outcomes. Some pages may need no change, and some requests may go unanswered; both are legitimate results to log.
Step 4. Optimize priority company pages
Questions This Section Answers
- Which observed BlueChew website pages should receive review briefs?
Company website page | Citation appearances in all captured answers | Benchmark answers citing the page | Recommending answers citing the page |
|---|---|---|---|
https://bluechew.com/blogs/medication/bluechew-vs-hims | 18 | 0 | 0 |
https://bluechew.com/our-stories/bluechew-vs-hims | 17 | 0 | 0 |
https://bluechew.com/our-stories/bluechew-vs-hims-who-wins-in-2026 | 16 | 0 | 0 |
https://bluechew.com/blogs/medication/online-ed-services-free-consultations | 12 | 8 | 7 |
https://bluechew.com/sildenafil | 12 | 0 | 0 |
https://bluechew.com/blogs/medication/bluechew-vs-lemonaid-health-vs-goodrx-care | 10 | 0 | 0 |
https://bluechew.com/our-stories/beginners-guide-to-bluechew | 9 | 0 | 0 |
https://bluechew.com/blogs/lifestyle/bluechew-vs-hims-who-wins-in-2026 | 8 | 0 | 0 |
The company's website was cited 307 times across 106 distinct page addresses; the table shows 8 pages selected for review. Zeros in the answer columns mean no matching answers were recorded. A cited page is not automatically a page that accompanied a recommendation.
BlueChew's own site is cited widely across the captured answers, but the selected pages show a striking pattern: most of the comparison and story pages were cited without appearing in benchmark answers that mention or recommend the company. One consultation-focused page is the exception, appearing in both mentioning and recommending answers.
That pattern suggests the comparison pages are being picked up for context rather than as the page that accompanies an endorsement. The agency would not assume the pages are weak; it would brief them around approved facts and the buyer questions the research actually recorded, then check existing coverage before proposing anything new.
Page briefs would specify the approved facts to use, the questions to answer and the internal links to add. Zeros in the answer columns mean no matching answers were recorded, not that a page is unused.
Step 5. Publish around buyer questions
Questions This Section Answers
- Which observed buyer questions support content briefs for BlueChew?
Question observed in the research | Benchmark answers to this question | Company mentions | Company recommendations |
|---|---|---|---|
What are the best online ED pills? | 3 | 3 | 2 |
What is the best online ED medication? | 3 | 3 | 2 |
What is the best online treatment for ED? | 3 | 3 | 2 |
What's the best ED medication online? | 3 | 3 | 2 |
What's the best ED treatment online? | 3 | 3 | 2 |
What's the best Viagra to buy online? | 2 | 2 | 2 |
What is the ED pill free trial? | 2 | 2 | 1 |
ed drugs online | 2 | 2 | 1 |
These are recorded answer observations, not search volume, verified demand, or proof of missing website content.
The recorded questions are mostly broad best-online-ED-treatment prompts, with a smaller group on free trials and buying Viagra online. BlueChew is mentioned in most of these answers and recommended in several, which makes them a sensible place to concentrate buyer-question content.
These are answer observations, not search volume or proof of missing website content. Before proposing a new page, the agency would check whether BlueChew already covers the question and whether the existing page is the one being cited. Where coverage exists, the brief would improve it rather than duplicate it.
Proposed content would answer the buyer question directly, using approved facts and clear comparisons, so an assistant has a citable, unambiguous source to draw on.
Our 90-day action plan
Questions This Section Answers
- How should the agency sequence the proposed BlueChew work and judge completion?
Period | Deliverable | Completion criterion |
|---|---|---|
Days 1–30 | Baseline scorecard, scoped fact-review register and page/source shortlist | Each record has an owner, evidence requirement and review status |
Days 31–60 | Approved page briefs and justified publisher requests | Separate confirmed edits, no-change decisions, requests and responses |
Days 61–90 | Buyer-content briefs and a fresh scorecard | Record work completed separately from measured answer outcomes and comparability limits |
The plan runs in three stages, each with a completion criterion tied to work done rather than to visibility results. The first stage establishes the baseline scorecard, the fact-review register and the page and source shortlist, with an owner and evidence requirement for every record.
The second stage produces approved page briefs and justified publisher requests, recording confirmed edits, no-change decisions, requests and responses as separate items. The third stage delivers buyer-content briefs and a fresh scorecard.
Delivered work is not the same as a measured outcome. The plan records what was completed and keeps that separate from any later change in the answers, along with the comparability limits that apply.
Methodology
Questions This Section Answers
- How are BlueChew answer metrics and citation populations defined?
This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 281 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.
An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.
The wider citation analysis covers 800 captured answers and 5650 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.
Monthly sample coverage:
Reporting month | Answers included | AI services covered | Services |
|---|---|---|---|
Oct 2026 | 296 | 6 | ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity |
Nov 2026 | 281 | 6 | ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity |
July 2026 measured a different set of companies, so it is excluded from this comparison. August 2026 measured a different set of companies, so it is excluded from this comparison. September 2026 measured a different set of companies, so it is excluded from this comparison.
The answer samples differ between months. These comparisons show how the recorded results changed; they do not establish why they changed.
The report covers a single month, and the exact dates the original answers were collected have not been verified. Visibility rates rest on the answers that met the benchmark's inclusion rules. A recommendation requires both an endorsement and positive wording, and shortlist and first-place counts sit inside recommendations rather than adding to them.
An answer can mention several companies, so company counts cannot be summed to find distinct answers. Sentiment describes answer wording, not customer satisfaction. The wider citation analysis covers more answers than the benchmark, and citation appearances are not the same as benchmark answers citing a page.
The monthly samples differ, so comparisons show how recorded results changed, not why. Current page contents and disputed claims still need independent verification.
Our first three priorities
The first priority is verification. The free-trial question is rated highest, so confirming the current position on trials, price and Gold composition comes before any page or publisher request. Until that is settled, briefs stay conditional and no correction is issued.
The second is the owned comparison pages. Most were cited without accompanying a mention or recommendation, so the agency would brief them around approved facts and the recorded buyer questions, checking existing coverage first. The consultation-focused page, which does appear alongside recommendations, is the natural model to learn from.
The third is buyer-question content on the broad best-treatment prompts, where BlueChew is already mentioned and sometimes recommended. A clear, citable answer page gives assistants a stronger source. Progress would be tracked on the scorecard as completed work, separate from any later movement in the answers.
/ Learn More
Understanding AI search visibility.
AI search experiences create answers by pulling information from many places online and summarizing it into a single response.
What Is AI Citation Intelligence?
What Is Citation Architecture?
What Is Generative Engine Optimization?
What Is AI Share of Voice?
Archived editions
Browse earlier published research snapshots for this article. The latest edition remains at the current URL.


